Drug Profile
Fedratinib - Celgene Corporation
Alternative Names: FEDR; INREBIC; Inrebic; SAR-302503; TG-101348Latest Information Update: 29 Jan 2024
Price :
$50
*
At a glance
- Originator TargeGen
- Developer Bristol-Myers Squibb; Celgene Corporation; Sanofi
- Class Antifibrotics; Antihaemorrhagics; Antineoplastics; Phenyl ethers; Pyrimidines; Pyrrolidines; Small molecules; Sulfonamides
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Janus kinase-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Myelofibrosis
- Discontinued Essential thrombocythaemia; Polycythaemia vera; Solid tumours
Most Recent Events
- 10 Dec 2023 Interim efficacy and adverse events data from the phase-III FREEDOM2 trial in Myelofibrosis presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 09 Dec 2023 Pharmacodynamics data from a preclinical trial in Myelofibrosis presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 08 Nov 2023 Celgene completes a phase-III trial in Myelofibrosis (Treatment-experienced) in USA and Canada (PO) (NCT03755518)